AVEO Pharmaceuticals Inc. (AVEO)

0.61
0.00 0.03
NASDAQ : Health Technology
Prev Close 0.61
Open 0.62
Day Low/High 0.60 / 0.63
52 Wk Low/High 0.56 / 3.59
Volume 2.45M
Avg Volume 3.58M
Exchange NASDAQ
Shares Outstanding 125.35M
Market Cap 82.02M
P/E Ratio N/A
Div & Yield N.A. (N.A)
AVEO Oncology To Present At The Morgan Stanley Global Healthcare Conference

AVEO Oncology To Present At The Morgan Stanley Global Healthcare Conference

AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, chief executive officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2013 at 12:55 p.

Aveo: Anatomy Of A Trade Gone Wrong

Aveo: Anatomy Of A Trade Gone Wrong

The FDA’s rejection of Aveo's Tivozanib is a stunner.

AVEO Oncology To Present At The Canaccord Genuity 33rd Annual Growth Conference

AVEO Oncology To Present At The Canaccord Genuity 33rd Annual Growth Conference

AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Canaccord Genuity 33 rd Annual Growth Conference on Thursday, August 15, 2013 at 2:00 p.

AVEO Reports Second Quarter 2013 Financial Results

AVEO Reports Second Quarter 2013 Financial Results

AVEO Oncology (NASDAQ: AVEO) today reported second quarter 2013 financial results.

AVEO: Insiders Vs. Shorts

AVEO: Insiders Vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 06/28/2013 settlement date, and AVEO Pharmaceuticals, Inc. is one of the most shorted stocks of the Russell 3000, based on 5.59 "days to cover" versus the median component at 3.80.

FDA's Flawed Call On Aveo's Tivozanib

FDA's Flawed Call On Aveo's Tivozanib

The FDA has let down renal cancer patients with its Tivozanib decision.

The 5 Dumbest Things on Wall Street This Week: June 7

The 5 Dumbest Things on Wall Street This Week: June 7

Scotts Miracle-Gro CEO swears like a sailor, Aveo sinks like the Titanic, Sprint's captain tries to capsize the Dish CEO's offer and more.

5 Dumbest Things on Wall Street

5 Dumbest Things on Wall Street

Scotts Miracle-No!, Synta's Sorrow and Google's Porn Problem highlight Gregg Greenberg's 5 Dumbest list this week.

Aveo's Future Depends on Triple-Negative Breast Cancer

Aveo's Future Depends on Triple-Negative Breast Cancer

Aveo's next chance to resurrect its flailing cancer drug will come in 2014/2015 with breast cancer study data.

Aveo Fires 140 Workers As Punishment For CEO's Incompetence

Aveo Fires 140 Workers As Punishment For CEO's Incompetence

The failure of a kidney cancer drug won't stop Aveo executives from cashing future paychecks.

Aveo Chairman: Expect 'Consequences" From Kidney Cancer Drug Debacle

Aveo Chairman: Expect 'Consequences" From Kidney Cancer Drug Debacle

Status quo reigns at struggling Aveo's shareholder meeting, but will planned changes include executive turnover?

2013 FDA Drug Approval Calendar

2013 FDA Drug Approval Calendar

An updated list of the biotech and drug firms expecting FDA drug approval decisions in 2013.

Aveo Screwed Up but Its Kidney Cancer Drug Is Real

Aveo Screwed Up but Its Kidney Cancer Drug Is Real

At some point, investors will give Aveo credit for tivozanib, says David Sobek.

3 Health Care Stocks Under $10 to Watch

3 Health Care Stocks Under $10 to Watch

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Bubble Fears Amid Relentless Market Climb

Bubble Fears Amid Relentless Market Climb

Strategists predict equity markets will be propelled higher with one warning of a bubble poised to be popped.

Fire Aveo's CEO for Incompetence and Arrogance Rivaling ImClone's Sam Waksal

Fire Aveo's CEO for Incompetence and Arrogance Rivaling ImClone's Sam Waksal

Heads need to roll at Aveo because of the FDA's thrashing of the company's kidney cancer drug.

Leaders of <I>TheStreet's</I> Drug Approval Contest

Leaders of TheStreet's Drug Approval Contest

This group of contestants have nearly perfect records picking FDA and European drug approvals.

Stock Futures Eye Rebound on ECB Stimulus, U.S. Data

Stock Futures Eye Rebound on ECB Stimulus, U.S. Data

Stock futures are looking to rebound from losses in the prior session.

Aveo, Delcath FDA Panel Live Blog

Aveo, Delcath FDA Panel Live Blog

Join TheStreet's Adam Feuerstein as he live blogs FDA advisory panels for Aveo Oncology and Delcath Systems

Why Aveo's Tivozanib Should Win FDA Approval

Why Aveo's Tivozanib Should Win FDA Approval

Aveo's Tivozanib kidney cancer drug will get the nod from regulators.

AVEO Pharmaceuticals Enters Oversold Territory (AVEO)

AVEO Pharmaceuticals Enters Oversold Territory (AVEO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Should Aveo Run Second Study of Kidney Cancer Drug, FDA Asks

Should Aveo Run Second Study of Kidney Cancer Drug, FDA Asks

Ahead of Thursday's FDA panel, the agency asks if Aveo should conduct a second clinical trial.

Prepping for Aveo, Delcath FDA Panels

Prepping for Aveo, Delcath FDA Panels

It's a big week for Aveo and Delcath, starting Tuesday with FDA reviews of their respective cancer products.

Cramer's 'Mad Money' Recap: Next Week's Game Plan

Cramer's 'Mad Money' Recap: Next Week's Game Plan

Cramer is keeping up with earnings all week and the unemployment numbers Friday.

Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail!

Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail!

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Aveo's Kidney Cancer Drug Won't Get FDA Panel OK

Aveo's Kidney Cancer Drug Won't Get FDA Panel OK

A close examination of survival data from Aveo's phase III study raises concerns.

Biotech's Next Big Thing: Aveo

Biotech's Next Big Thing: Aveo

TheStreet Sr. Columnist Adam Feuerstein says FDA reviews for cancer drugs from Aveo and Delcath are the next big thing in biotech.

4 Health Care Stocks Under $10 to Watch

4 Health Care Stocks Under $10 to Watch

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Most Profitable Second Quarter Biotech Stocks

Most Profitable Second Quarter Biotech Stocks

A list of stock-moving biotech catalysts includes FDA drug approvals, clinical trial results and closely-followed medical meetings.

TheStreet Quant Rating: D- (Sell)